Smith Ernest S. 4
4 · VACCINEX, INC. · Filed Apr 2, 2021
Insider Transaction Report
Form 4
VACCINEX, INC.VCNX
Smith Ernest S.
SVP, Research & CSO
Transactions
- Award
Stock Option (Right to Buy)
2021-04-02+10,000→ 10,000 totalExercise: $2.93Exp: 2031-04-02→ Common Stock (10,000 underlying)
Holdings
- 8,000
Common Stock
- 40,729
Stock Option (Right to Buy)
Exercise: $7.10Exp: 2025-12-22→ Common Stock (40,729 underlying) - 5,110
Stock Option (Right to Buy)
Exercise: $7.10Exp: 2025-12-23→ Common Stock (5,110 underlying) - 8,000
Stock Option (Right to Buy)
Exercise: $3.90Exp: 2029-03-14→ Common Stock (8,000 underlying) - 8,000
Stock Option (Right to Buy)
Exercise: $6.07Exp: 2030-02-24→ Common Stock (8,000 underlying)
Footnotes (4)
- [F1]Exercisable in full as of the date of this report.
- [F2]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date.
- [F3]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date.
- [F4]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date.